FUNDAMENTALS · Fundamentals · US Healthcare

Nephros (NEPH) Fundamentals 2026 — P/E 50.0x, Revenue Analysis | SniperIQ

Nephros (NEPH) is a US-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of $40M, trading at

.66 on the NASDAQ. This SniperIQ fundamentals page covers Nephros's valuation (P/E 50.0x, P/B 3.6x), profitability (net margin 4.1%), revenue (
9M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$40M
P/E (TTM)50.0x
Net Margin4.1%
Revenue (FY25)
9M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Nephros's market cap?

Nephros (NEPH) has a market capitalization of approximately $40M, trading at

.66 on the NASDAQ. Market cap moves with the live share price.

What is Nephros's P/E ratio?

Nephros's trailing twelve-month P/E ratio is 50.0x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Nephros?

Nephros runs a net profit margin of 4.1%, a gross margin of 59.1%, and an operating margin of 3.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Nephros generate?

Nephros reported revenue of

9M for fiscal year 2025, with net income of
M and earnings per share (EPS) of 0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Nephros pay a dividend?

Nephros does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Nephros financially healthy?

Nephros carries a debt-to-equity ratio of 0.09x and a current ratio of 4.55x, with a market beta of 1.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Nephros a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Nephros (NEPH) the key facts are: market cap $40M, P/E 50.0x, revenue

9M, 52-week range 2.66-6.42. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Nephros's full fundamentals live

Get Nephros's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.